Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut; and.
Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.
J Nucl Med. 2024 Oct 1;65(10):1512-1517. doi: 10.2967/jnumed.123.267215.
Bispecific antibodies (bsAbs) are engineered to target 2 different epitopes simultaneously. About 75% of the 16 clinically approved bsAbs have entered the clinic internationally since 2022. Hence, research on biomedical imaging of various radiolabeled bsAb scaffolds may serve to improve patient selection for bsAb therapy. Here, we provide a comprehensive overview of recent advances in radiolabeled bsAbs for imaging via PET or SPECT. We compare direct targeting and pretargeting approaches in preclinical and clinical studies in oncologic research. Furthermore, we show preclinical applications of imaging bsAbs in neurodegenerative diseases. Finally, we offer perspectives on the future directions of imaging bsAbs based on their challenges and opportunities.
双特异性抗体（bsAbs）被设计为同时靶向 2 个不同的表位。自 2022 年以来，约有 75%的 16 种临床批准的 bsAbs 已在国际上进入临床应用。因此，研究各种放射性标记 bsAb 支架的生物医学成像可能有助于改善 bsAb 治疗的患者选择。在这里，我们全面概述了用于通过 PET 或 SPECT 成像的放射性标记 bsAbs 的最新进展。我们比较了直接靶向和预靶向方法在肿瘤学研究中的临床前和临床研究中的应用。此外，我们展示了成像 bsAbs 在神经退行性疾病中的临床前应用。最后，我们根据成像 bsAbs 的挑战和机遇对其未来发展方向提出了看法。
